My bookmarks

Pins are saved using cookies. Deleting them from your browser will delete your preferences.

Menu

Gene Tech Opens Doors

18 July 2019

Your genes determine more than your eye color or your physique. The propensity of you or your offspring to develop certain diseases is highly influenced by genetics.

The good news is research into the genome, your complete set of genes, has started to drive huge medical breakthroughs and new drugs are regularly approved for people with rare genetic conditions. As a result investment opportunities up and down the genomic food chain are plentiful.

  • The cost of sequencing the human genome has declined considerably since 2001. According to Illumina, the premiere provider of genetic analysis technology, its goal is to reach a $100 cost sometime in the future. To date over 1.5 million genomes have been sequenced and studied.
  • Next-generation sequencing (NGS), which allows for analysis of the genome, is reducing the costs of treatment and improving the accuracy of diagnosis and the efficacy of treatment. As NGS advances, the research and development of drugs and diagnostic tools continue to accelerate.
  • Gene analysis is a priority worldwide. In the U.S. the All of Us study is geared to find genetic links to diverse diseases. Additionally, over 40 countries internationally are also analyzing the gene sequences of their citizens. These discoveries will spur even more research into diseases that can be targeted.
  • Investment opportunities exist in medical tools companies that are discovering the links between genes and medical conditions, testing companies that identify genetic abnormalities and biotechnology and pharmaceutical companies that develop products to treat the diseases that stem from genetic mutations.
La Française Group provides access to the expertise of a number of asset management companies around the world. To provide you with the most relevant information, we have developed an interface to present the full range of products available for your investor profile and country of residence.
Present yourself
1
Country
2
Language
3
Profile
Your country of residence
Your language
Your profile
<p class="new-disclaimer__legal-notice">Before consulting this website, for your protection and in your interest, please read the “<a href="en/legal-notice/" target="_blank">disclaimer</a>” and “<a href="en/regulatory-information/" target="_blank">current regulations</a>” carefully. This information explains certain legal and regulatory restrictions which apply to individual and professional investors according to local law. By accessing this site, in my non-professional or professional capacity, I acknowledge that I have read and accept the terms and conditions of use. Pursuant to the application of the European Markets in Financial Instruments Directive (“MiFID”), please state to which category of investor you belong&nbsp;:</p>
<p class="new-disclaimer__legal-notice">Before consulting this website, for your protection and in your interest, please read the “<a href="en/legal-notice/" target="_blank">disclaimer</a>” and “<a href="en/regulatory-information/" target="_blank">current regulations</a>” carefully. This information explains certain legal and regulatory restrictions which apply to individual and professional investors according to local law. By accessing this site, in my non-professional or professional capacity, I acknowledge that I have read and accept the terms and conditions of use. Pursuant to the application of the European Markets in Financial Instruments Directive (“MiFID”), please state to which category of investor you belong&nbsp;:</p>
By continuing browsing on this website, you accept the use of cookies and other tracing devices s as to allow you to receive information suited to your profile, facilitate information sharing on social networks, guarantee the best browsing experience possible and to create statistics. To find out more, we invite you to consult our Privacy and Cookies policy. Find out more.